Anti-TIM-3 and Anti-PD-1 Antibody Combination for Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors, such as radiotherapy, chemotherapy, and surgery, have limitations in addressing malignant tumors with high metastasis rates and poor treatment outcomes, necessitating the development of more effective immunotherapy approaches.
Innovation Solution
A pharmaceutical combination of an anti-TIM-3 antibody and an anti-PD-1 antibody, or their antigen-binding fragments, is administered to block immune checkpoint signaling pathways, enhancing anti-tumor effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional treatment methods (radiotherapy, chemotherapy, surgery) are used, then tumor symptoms can be alleviated and survival period prolonged, but treatment outcomes remain poor for malignant tumors with high metastasis rates
Solution Approach 1:
The patent combines anti-TIM-3 antibody and anti-PD-1 antibody into a pharmaceutical composition that works synergistically to block multiple immune checkpoint pathways simultaneously, achieving enhanced anti-tumor efficacy that overcomes the limitations of conventional single-modality treatments
2Reliability
If single immune checkpoint inhibition is used, then some anti-tumor activity is achieved, but the effect is insufficient for tumors with high metastasis rates
Solution Approach 1:
The patent merges two different immune checkpoint inhibition mechanisms (TIM-3 and PD-1 pathways) into a single pharmaceutical composition, creating a multi-targeted therapy that demonstrates broad efficacy across different tumor types including non-small cell lung cancer, small cell lung cancer, and lymphoma
Solution Approach 2:
The pharmaceutical composition is designed to universally target multiple immune checkpoint pathways that are commonly upregulated across various tumor types, making it applicable to a broad range of malignancies with high metastasis rates
Data Source
AI summary
A drug combination of an anti-TIM-3 antibody and an anti-PD-1 antibody includes an anti-TIM-3 antibody or an antigen-binding fragment thereof, and an anti-PD-1 antibody or an antigen-binding fragment thereof. A kit for treating tumors also includes the drug combination. In addition, the drug combination is applied in preparing a drug for treating tumors, and a method treats tumors by using the drug combination.